208 related articles for article (PubMed ID: 37179293)
1. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract][Full Text] [Related]
2. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
Front Oncol; 2022; 12():946319. PubMed ID: 36212445
[TBL] [Abstract][Full Text] [Related]
3. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Fanale D; Incorvaia L; Badalamenti G; De Luca I; Algeri L; Bonasera A; Corsini LR; Brando C; Russo A; Iovanna JL; Bazan V
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925671
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.
Bian B; Fanale D; Dusetti N; Roque J; Pastor S; Chretien AS; Incorvaia L; Russo A; Olive D; Iovanna J
Oncoimmunology; 2019; 8(4):e1561120. PubMed ID: 30906655
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
8. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
10. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract][Full Text] [Related]
11. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
12. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
Billon E; Chanez B; Rochigneux P; Albiges L; Vicier C; Pignot G; Walz J; Chretien AS; Gravis G; Olive D
Front Immunol; 2021; 12():670827. PubMed ID: 33959132
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
14. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
17. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
19. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]